REM Group (Holdings) Full Year 2024 Earnings: EPS: HK$0.001 (vs HK$0.004 in FY 2023)

REM Group (Holdings) (HKG:1750) Full Year 2024 Results

Key Financial Results

• Revenue: HK$140.8m (down 16% from FY 2023).
• Net income: HK$1.66m (down 76% from FY 2023).
• Profit margin: 1.2% (down from 4.2% in FY 2023). The decrease in margin was driven by lower revenue.
• EPS: HK$0.001 (down from HK$0.004 in FY 2023).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

The primary driver behind last 12 months revenue was the Hong Kong segment contributing a total revenue of HK$133.0m (94% of total revenue). Notably, cost of sales worth HK$104.2m amounted to 74% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to HK$31.9m (87% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of HK$1.60m. Explore how 1750's revenue and expenses shape its earnings.

REM Group (Holdings) shares are down 5.4% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 3 warning signs for REM Group (Holdings) (1 doesn't sit too well with us!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.